Eli Lilly and Co. (LLY) and Incyte Corp. (INCY) announced Monday initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
from RTT - Biotech https://ift.tt/2DWK9jI
via IFTTT
No comments:
Post a Comment